Imeik Technology Development Co., Ltd. (300896.SZ) engages in the research, development, production and sales of biomedical soft tissue repair materials principally for aesthetic medicine applications in China. The company offers a broad portfolio of aesthetic products including cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere, polylactic acid-based dermal fillers, poly-p-dioxanone facial implant threads, medical sodium hyaluronate-hydroxypropyl methylcellulose gel, sodium hyaluronate composite solution for injection, modified sodium hyaluronate gel for injection, and medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel; it also provides skin care products targeting the broader health and beauty sectors. Founded in 2004 and headquartered in Beijing, China, Imeik operates primarily in the domestic market with expanding international presence through strategic initiatives. In recent developments, the company plans to acquire an 85% stake in South Korea's REGEN Biotech for approximately USD190 million via a joint venture with an investment fund, aiming to integrate Regen's research, production and sales capabilities as its global business platform; it additionally allocates around CNY1 billion for potential acquisitions over the next two years and pursues partnerships with leading academic institutions to enhance innovation.